A study of eribulin in combination with trastuzumab and pertuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results assessing effectiveness and safety of E combined with trastuzumab with P as first and second line treatment for metastatic or advanced BC presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 24 Aug 2020 Results published in the Investigational New Drugs
- 12 Jan 2018 New trial record